Corporate Members

Diamond Elite





Latest News


Reimbursement Update Permanent J code for Imfinzi

IMFINZI is indicated for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.  The NEW Permanent J-Code is J91731 and goes into effect January 1, 2019.

ASH 2018 News From Genentech

This year at the American Society of Hematology (ASH) Annual Meeting, Genentech presented data for ten medicines in more than 70 abstracts, including 25 oral presentations [press release]. Highlighted data included new data from three Venclexta® (venetoclax) combination studies demonstrating deep responses in chronic lymphocytic leukemia and acute myeloid leukemia, two of the most common types...

Entrinsic Health Solutions and Markey Cancer Center Launch Phase II Study for Neuroendocrine Tumor Patients with Quality of Life-Limiting Diarrhea

NORWOOD, Mass., Dec. 12, 2018 /PRNewswire/ — Entrinsic Health Solutions in partnership with the University of Kentucky (UK) Markey Cancer Center today announced initiation of active accrual and first consented patient in its Phase II study evaluating enterade® – a glucose-free, medical food – in neuroendocrine tumor and carcinoid syndrome patients. Findings from this study may show that enterade can...

Announcing a New First-Line Indication for a Genentech Therapy

Click here to learn more.   TECENTRIQ PI Genentech isexcited to share the news of a new FDA-approved indication. TECENTRIQ®(atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel, andcarboplatin, is now indicated for the first-line treatment of patientswith metastatic non-squamous non-small cell lung cancer (nsqNSCLC) with no EGFRor ALK genomic tumor aberrations. Please see the attached TECENTRIQ 1L NSCLC...

Permanent J-codes for Genentech Hematology Products

 The Centers for Medicare & Medicaid Services (CMS) has made a change to the RITUXAN® (rituximab) J-code and has assigned a permanent J-code for RITUXAN HYCELA® (rituximab/hyaluronidase human subcutaneous injection). Effective January 1, 2019 J-code J9312 will replace J9310 for RITUXAN and the billable units will change from 100 mg to 10 mg. Additionally, the...

Who’s Online

There are no users currently online